|Dr. Frederic Guerard Pharm.D.||Pres, CEO & Director||873.62k||N/A||1972|
|Mr. Robert S. Breuil||Chief Financial Officer||441.08k||N/A||1962|
|Dr. Gerald D. Cagle Ph.D.||Sr. Advisor, Head of Bus. Devel. & Director||11.17k||N/A||1944|
|Dr. Parisa Zamiri M.D., Ph.D.||Chief Medical Officer||468.51k||N/A||1965|
|Dr. Peter A. Campochiaro M.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Peter J. McDonnell||Co-Founder||N/A||N/A||1959|
|Ms. Bettina Maunz||Chief People Officer & Head of Communications||N/A||N/A||N/A|
|Mr. Ming Yang||Sr. VP of R&D||N/A||N/A||N/A|
|Dr. Ward M. Peterson Ph.D.||Sr. VP of Preclinical Devel.||N/A||N/A||N/A|
|Mr. Ali Kakavand||VP & Head of Program Management||N/A||N/A||N/A|
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Graybug Vision, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.